背景:LINC00324是一种长链非编码RNA,在各种癌症中异常表达,并与不良预后和临床特征有关。它涉及多种致癌分子途径影响细胞增殖,迁移,入侵,和凋亡。然而,表达式,函数,LINC00324在胶质瘤中的作用机制尚未见报道。
方法:我们基于来自癌症基因组图谱(TCGA)和基因型组织表达(GTEx)的数据评估了LINC00324和LINC00324在神经胶质瘤患者中的表达,以确定与LINC00324相关的神经胶质瘤发病机制有关的通路。
结果:根据我们的发现,我们观察到LINC00324在胶质瘤患者肿瘤和正常组织中的差异表达。我们对总生存期(OS)和疾病特异性生存期(DSS)的分析表明,与LINC00324低表达的神经胶质瘤患者相比,高表达的神经胶质瘤患者的预后较差。通过整合TCGA患者的临床数据和遗传特征,我们开发了一个列线图来预测神经胶质瘤患者的OS和DSS。基因集富集分析(GSEA)揭示了几种途径,包括JAK/STAT3信令,上皮-间质转化,STAT5信令,NF-κB激活,和细胞凋亡,在具有高LINC00324表达的神经胶质瘤样品中差异富集。此外,我们观察到LINC00324表达之间的显着相关性,免疫浸润水平,免疫检查点相关基因的表达(HAVCR2:r=0.627,P=1.54e-77;CD40:r=0.604,P=1.36e-70;ITGB2:r=0.612,P=6.33e-7;CX3CL1:r=-0.307,P=9.24e-17)。这些发现强调了LINC00324在神经胶质瘤进展中的潜在意义,并为进一步研究和潜在治疗靶点提供了途径。
结论:确实,我们的结果证实,LINC00324标志有望作为神经胶质瘤患者的预后预测因子.这一发现为了解这种疾病开辟了新的可能性,并可能为靶向治疗的发展提供有价值的见解。
BACKGROUND: LINC00324 is a long-stranded non-coding RNA, which is aberrantly expressed in various cancers and is associated with poor prognosis and clinical features. It involves multiple oncogenic molecular pathways affecting cell proliferation, migration, invasion, and apoptosis. However, the expression, function, and mechanism of LINC00324 in glioma have not been reported.
METHODS: We assessed the expression of LINC00324 of LINC00324 in glioma patients based on data from The Cancer Genome Atlas (TCGA) and Genotype-Tissue Expression (GTEx) to identify pathways involved in LINC00324-related glioma pathogenesis.
RESULTS: Based on our findings, we observed differential expression of LINC00324 between tumor and normal tissues in glioma patients. Our analysis of overall survival (OS) and disease-specific survival (DSS) indicated that glioma patients with high LINC00324 expression had a poorer prognosis compared to those with low LINC00324 expression. By integrating clinical data and genetic signatures from TCGA patients, we developed a nomogram to predict OS and DSS in glioma patients. Gene set enrichment analysis (GSEA) revealed that several pathways, including JAK/STAT3 signaling, epithelial-mesenchymal transition, STAT5 signaling, NF-κB activation, and apoptosis, were differentially enriched in glioma samples with high LINC00324 expression. Furthermore, we observed significant correlations between LINC00324 expression, immune infiltration levels, and expression of immune checkpoint-related genes (HAVCR2: r = 0.627, P = 1.54e-77; CD40: r = 0.604, P = 1.36e-70; ITGB2: r = 0.612, P = 6.33e-7; CX3CL1: r = -0.307, P = 9.24e-17). These findings highlight the potential significance of LINC00324 in glioma progression and suggest avenues for further research and potential therapeutic targets.
CONCLUSIONS: Indeed, our results confirm that the LINC00324 signature holds promise as a prognostic predictor in glioma patients. This finding opens up new possibilities for understanding the disease and may offer valuable insights for the development of targeted therapies.